Zehna Therapeutics to Present at Biotech Showcase™ 2023
A New Paradigm in the Treatment of CKD
CLEVELAND, Ohio, January 9, 2023 — Zehna Therapeutics, Inc., a biotechnology company focused on the development of therapeutics to slow the progression of chronic kidney disease, today announced that Camilla Simpson, Chief Executive Officer, will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.
The presentation will provide an overview of Zehna’s business and an update on its programs.
Details of the presentation are as follows:
Event: Biotech Showcase 2023
Date: Wednesday, January 11, 2023
Time: 2:15 PM PST
For access to the webinar, please follow this link.
Zehna management will be available for one-on-one meetings throughout the conference. The webcast recording will be available for six months after the presentation.
About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
About Zehna Therapeutics
Zehna Therapeutics is developing non-bactericidal small molecule inhibitors of a specific gut-microbial pathway clinically and mechanistically linked with chronic metabolic diseases. Zehna’s compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine and subsequently to trimethylamine N-oxide (TMAO) within the host. High systemic levels of TMAO have been linked to accelerated development of both cardiovascular (CVD) and chronic kidney disease (CKD), as demonstrated in CKD and CVD animal models and large-scale clinical cohort studies.
Please visit the Company’s website at zehnatx.com for more information.
Investors and Media Contact:Download PDF